Eli Lilly to buy Merida Biosciences in deal worth up to $2.88 billion
13 Articles
13 Articles
Lilly to Buy Merida for $2.88 Billion for Autoimmune Expansion
Eli Lilly & Co. plans to buy Merida Biosciences Inc. for as much as $2.88 billion in cash to expand in autoimmune and allergic diseases, part of an effort to build beyond the weight-loss and diabetes markets that made it the largest pharmaceutical company in the world.
Eli Lilly continues its rapid pace of acquisitions and has announced an agreement to buy the biotechnology company Merida Biosciences for up to US$2.87 billion, strengthening the pharmaceutical company's immunology portfolio. Exclusive content for subscribers. For full access, follow the link to the article and register.
The US pharmaceutical company acquires Merida Biosciences and thus continues its shopping tour. The race on the market for weight loss medications is getting closer
(Teleborsa) - Eli Lilly, a US pharmaceutical giant, has reached a final agreement for the acquisition of Merida Biosciences, a biotechnology company engaged in the development of a new class of...
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
